Kjell Arne Johansson
- Phone+47 55 58 61 64
- Visitor AddressKalfarveien 31
- Postal AddressPostboks 78045020 Bergen
Kjell Arne Johansson is working academically as a professor of medical ethics and philosophy of science, Department of Global Public Health and Primary Care, University of Bergen and clincially as a physician in the field of drug addiction, Department of Drug Addiction, Haukeland University Hospital.
Kjell Arne Johansson has many years of experience in conducting research on population ethics and in developing novel methods for fair priority setting in global health and in applying them to low- and high-income country settings. His key competencies are: population ethics and distributive implications of health care, including economic evaluations, equality of health outcomes and financial risk protection. Over the last five years, his research focus has been on applied equity impact modelling, seeking to understand the broader implications of improved health care coverage by using mathematical population models. In particular, he has contributed to three equity impact methods: Extended Cost Effectiveness analysis (ECEAs), severity of disease analysis and Distributive Cost Effectiveness Analysis (DCEA). He is now the president of the International Society for Priority Setting in Health (ISPH).
Core competencies: clinical ethics and bedside rationing; economic evaluation, including CEA, ECEA and DCEA; global health; priority setting in health care.
2005-current Responsible, together with Ingrid Miljeteig, for teaching at courses in medical ethics for medical students at University of Bergen.
2007-current The ethics of global health and priority setting (part of general course in Global Health, 30 ECTS). Responsibility in establishment of this course, and now teaching.
2007-current Responsible for teaching in ethics of priority setting in global health in various courses for graduate students at Master level, Centre for International Health, University of Bergen
2005-current Several 1-2 hour lectures on medical ethics and priority setting at different courses arranged at the Faculty of Medicine and elsewhere (e.g. Human Rights, International Health, Refugees, Autonomy, Priority Setting, Reproductive Health, Social Determinant of Health, Specialist courses for Medical Doctors)
Supervision of graduate students:
Completed supervision: 3 PhDs (main supervisor), 3 Master's (main and co-supervisor), 2 PhD tracks (main supervisor), 9 research theses for medical students
Supervision in progress: 1 PhD (main supervisor), 7 PhDs (co-supervisor), 4 Master’s (co-supervisor
20 latest peer-reviewed publications
2018-current Chair of International Society for Priority Setting in Health
2017 (jan.august) Head of teaching at Dpt. of Global Public Health and Primary Care
2016 (jan-aug)Leader of Bergen Addiction Research group, Haukeland University Hospital
2013-2015 Leader of Global Health Priorities (research group with seven senior researchers and more than 15 PhD students), Department of Global Public Health, University of Bergen
2013-2014 Leader of Profession Group in teaching of Public Health and Epidemiology (teaching consortium for around 30 academics with educational responsibilities), Department of Global Public Health, University of Bergen
2013-2015 Leader of research project Global Health Priorities 2020, research grant from Research Council of Norway
2007-2008 Member of Faculty Research Board, Faculty of Medicine and Dentistry, UiB
At Bergen Center for Ethics and Priority Setting (BCEPS), Kjell Arne Johansson is leading two of the five work packages the center is organized around the next five years; a) priority decision support tools; and b) essential health care package for NCDI in Zanzibar.
- Providing efficient, effective and equitable health care in Ethiopis
This Bill & Melinda Gates Foundation (BMGF) funded project will involve capacity-building at Ethiopia’s Federal Ministry of Health (FMOH). Entitled Disease Control Priorities-Ethiopia (DCP-E), the project will train Ethiopian researchers and policymakers in health economics, decision sciences and priority setting. The training will enable them to generate an evidence base for designing, developing and implementing essential health services for FMOH, and may be used, in particular, to help revise Ethiopia’s current essential health services package.
Poverty and Equity cKMC
- Community initiated Kangaroo Mother Care for low birth weight infants: a poverty and equity impact evaluation
Embedded in the ongoing main CISMAC trial, which estimates the survival benefits of promoting Kangaroo Mother Care at home (cKMC) to low birth weight (LBW) babies, this study will use the concentration index to estimate whether socioeconomic inequality in neonatal and early infant survival is more pronounced in the intervention or in the control groups. Further, this extension of the trial will estimate the household out-of-pocket expenses for illnesses that may be prevented by cKMC. It will also assess the extent to which out-of-pocket expenses for health care contribute to household impoverishment. Should cKMC prove effective in enhancing equity in child survival and in substantially reducing family expenditures, possibly even preventing catastrophic health expenditures, the findings of this added study could be of critical importance for scaling up Kangaroo Mother Care in India, as well as in other countries where many babies are born with LBW. Together with Sarmila Mazumder, Society for Applied Studies, India, Kjell Arne Johansson is the principal investigator.
- Integrated treatment of hepatitis C virus infection: a randomised controlled trial
This is a randomised controlled trial that estimates the effect of providing integrated hepatitis C treatment to patients with injecting opioid addiction. Those receiving medically assisted rehabilitation (MAR) often have poorer access to health care than the general population, and between 50-70% of all injectiong drug users in Bergen are estimated to be infected with hepatitis C virus. To end the hepatitis C epidemic, finding the best delivery platforms to provide the new and expensive antiviral heaptitis C drugs is crucial. Therefore, this study will provide new knowledge about how to improve patient care, MAR healthcare and to help access more of those in need of hepatitis C treatment. We want to test if integrated treatment is more effective than today's model.